Payment overview · 2025
General Payments
$194.83
10 reported records · 6 companies
Healthcare provider profile · identity verified
Daniel Walter Yarrish, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SALT LAKE CITY, UT · NPI 1235240110
Verified facts
What the public records show
CMS Open Payments records show Daniel Walter Yarrish, MD received $194.83 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.69 | 26.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.40 | 22.8% | 2 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $37.61 | 19.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.56 | 15.2% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.64 | 9.1% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $14.93 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $194.83 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.40 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.40 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.56 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| BD Onclarity Normalized: bd onclarity |
Device | Becton, Dickinson and Company | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 76 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 19 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
76 | 76 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
194 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1094 | 263 |
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 173 |
| Omeprazole | Omeprazole | 439 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 364 | 100 |
| Lisinopril | Lisinopril | 356 | 98 |
| Losartan Potassium | Losartan Potassium | 351 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 296 | 82 |
| Sertraline Hcl | Sertraline Hcl | 292 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 80 |
| Trazodone Hcl | Trazodone Hcl | 269 | 77 |
| Potassium Chloride | Potassium Chloride | 266 | 78 |
| Alprazolam | Alprazolam | 253 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 251 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 242 | 59 |
| Metformin Hcl | Metformin Hcl | 229 | 67 |
| Citalopram Hbr | Citalopram Hydrobromide | 224 | 55 |
| Gabapentin | Gabapentin | 223 | 68 |
| Furosemide | Furosemide | 219 | 70 |
| Eliquis | Apixaban | 194 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 47 |
| Simvastatin | Simvastatin | 170 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 164 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 45 |
| Carvedilol | Carvedilol | 161 | 44 |
| Celecoxib | Celecoxib | 160 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 156 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 148 | 26 |
| Clonazepam | Clonazepam | 143 | 26 |
| Meloxicam | Meloxicam | 140 | 40 |
| Tramadol Hcl | Tramadol Hcl | 140 | 30 |
| Donepezil Hcl | Donepezil Hcl | 139 | 41 |
| Bupropion Xl | Bupropion Hcl | 138 | 35 |
| Finasteride | Finasteride | 131 | 39 |
| Montelukast Sodium | Montelukast Sodium | 129 | 41 |
| Aripiprazole | Aripiprazole | 126 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 53 |
| Glimepiride | Glimepiride | 118 | 28 |
| Ozempic | Semaglutide | 117 | 21 |
| Temazepam | Temazepam | 117 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 30 |
| Allopurinol | Allopurinol | 109 | 28 |
| Metformin Hcl Er | Metformin Hcl | 106 | 29 |
| Spironolactone | Spironolactone | 105 | 27 |
| Estradiol | Estradiol | 100 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 97 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 93 | 71 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 26 |
| Lorazepam | Lorazepam | 89 | 24 |
| Synthroid | Levothyroxine Sodium | 86 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 23 |
| Azithromycin | Azithromycin | 83 | 68 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 26 |
| Pregabalin | Pregabalin | 79 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 22 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 76 | 76 |
| Fentanyl | Fentanyl | 76 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 22 |
| Alendronate Sodium | Alendronate Sodium | 73 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 72 | 20 |
| Valsartan | Valsartan | 70 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 20 |
| Famotidine | Famotidine | 64 | 18 |
| Prednisone | Prednisone | 64 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 63 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 63 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | 17 |
| Ibuprofen | Ibuprofen | 61 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 15 |
| Xarelto | Rivaroxaban | 58 | 12 |
| Memantine Hcl | Memantine Hcl | 57 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 32 |
| Atenolol | Atenolol | 52 | 11 |
| Diazepam | Diazepam | 52 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 13 |
| Valacyclovir | Valacyclovir Hcl | 49 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | 15 |
| Jardiance | Empagliflozin | 47 | 11 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 18 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 13 |
| Methylprednisolone | Methylprednisolone | 40 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 23 |
| Cephalexin | Cephalexin | 36 | 22 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Lamotrigine | Lamotrigine | 34 | 11 |
| Ondansetron Odt | Ondansetron | 34 | 17 |
| Propranolol Hcl | Propranolol Hcl | 34 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Ramipril | Ramipril | 31 | suppressed |
| Cefdinir | Cefdinir | 29 | 25 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Naproxen | Naproxen | 27 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Ofloxacin | Ofloxacin | 22 | 14 |
| Mupirocin | Mupirocin | 21 | 13 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | 11 |
| Topiramate | Topiramate | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 11 |
| Gemtesa | Vibegron | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Digoxin | Digoxin | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dicloxacillin Sodium | Dicloxacillin Sodium | 12 | suppressed |
| Estrace | Estradiol | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $194.83 · 10 records | PFIZER INC. | ABRYSVO, AREXVY, BD Onclarity, COMIRNATY, PREVNAR 20, QULIPTA, SHINGRIX, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error